Sign Out
Posaconazole delayed release tablets are indicated for the prophylaxis of invasive Aspergillus and Candida infections, including both yeasts and molds, in patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or hematopoietic stem cell transplant (HSCT) recipients.
Posaconazole delayed release tablets are indicated for use in the treatment of the following fungal infections in patients 13 years of age or older: Refractory Invasive Fungal infections (IFI)/Intolerant Patients with IFI: Fusariosis, zygomycosis, cryptococcosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients with disease refractory to other therapy, or patients who are intolerant of other therapy. Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.
Continue with Google